When.does.mepolizumab go.off patent?

Short answer:
The main U.S. patents covering mepolizumab (brand name Nucala) are expected to expire in 2025 (and possibly 2026), although a handful of secondary patents and data‑protect‑type exclusivities could keep the drug under a form of protection a few years longer.

Why 2025–2026?

• The primary invention patents (e.g., U.S. Pat. 7,295,294 issued 2005) expire in 2025.
• A few method‑of‑manufacture patents filed in the 2010s could extend legal protection until the early‑to‑mid‑2030s, but these are not normally considered when a generic seeks approval.
• Orphan‑drug exclusivity (5 years from first FDA approval) and generic‑exclusivity (10 years from first generic filing) will already have lapsed, so the key barrier to a generic is the primary invention patents.

What does this mean for generics?

1. Patent expiry → first chance for a generic
   Once the main patents expire, the first generic applicant can file a BLA (Biologics License Application). The FDA will review the application for biosimilarity, and if approved, the generic (or “biosimilar”) can enter the market.

2. Market entry usually 1–2 years after patent expiry
   Even after the patents expire, there is a regulatory and commercial lag: the applicant must complete the biosimilar studies, obtain FDA approval, and the brand manufacturer may launch a patent‑busting strategy (e.g., extended‑release formulations, new indications). In practice, we see most biologic generics debut 2–4 years after the main patents expire.

3. Potential secondary patents
   GSK may own a handful of secondary patents (e.g., formulation, delivery device) that could be invoked to delay generic entry. However, these are often challenged in court or deemed non‑infringing by biosimilar applicants.

Bottom line

• Mepolizumab’s primary U.S. patents expire in 2025 (some secondary patents may keep a narrower exclusivity window until 2027–2029).
• Generic/biosimilar approval is likely to follow in 2026–2028, depending on the speed of the regulatory review and the strategic actions of GSK.
• Keep an eye on FDA announcements – the first biosimilar approval will be announced publicly once the FDA grants it.

Feel free to ask if you’d like to dive deeper into specific patents, international expiration dates, or the biosimilar approval process!